Hepatopancreatobiliary (HPB) sarcomas are uncommon types of malignancy that usually have a poor prognosis (
1,
2). Primary sarcomas of the pancreatic region are even rarer with a worse prognosis because of a delayed diagnosis (
3,
4). Due to some progression in genomic sequence findings in these malignancies, new data has been developed regarding their molecular arrangement (
5,
6). Amongst pancreatic sarcoma subtypes, leiomyosarcoma has been the most frequently reported one, but in other biliary sarcomas, there are different subtypes with varied prognoses and courses (
7-
9).
Hepatopancreatobiliary sarcoma cases usually present as obstructive jaundice with increased bilirubin and liver enzyme levels (
10). Despite the fact that this presentation might assist in earlier diagnosis, it usually occurs when the tumor is at late stages with a short survival period (
11,
12). The diagnosis of HPB sarcoma is usually made by non-invasive imaging modalities such as ultrasound, magnetic resonance imaging, computed tomography, and occasionally invasively endoscopic retrograde cholangiopancreatography (
13,
14). Acknowledgment of the clinical subtypes, patterns, and main characteristics may prompt diagnosis and treatment. Hence in this study, the epidemiological characteristics of cases with HPB sarcoma among Iranian patients were assessed to report the incidence patterns of HPB in Iran from 2010 to 2014, according to available data.